托珠单抗治疗难治性大动脉炎的长期疗效与安全性:TAKT 研究最终结果
TAKT 研究开放标签延长期纳入 36 例完成随机双盲期的难治性大动脉炎患者,每周皮下注射托珠单抗 162 mg 最长超过 96 周。结果显示糖皮质激素剂量较入组前复发时显著下降,46.4% 患者减至 <0.1 mg/kg/日,多数患者影像学改善或稳定,生活质量评分改善并维持,未报告新的安全性问题。
要点
- 长期托珠单抗治疗具有激素节约效应,46.4% 患者激素减至 <0.1 mg/kg/日。
- 96 周时 67.9% 患者影像学稳定、17.9% 改善,生活质量评分临床改善并维持。
- 每周皮下托珠单抗 162 mg 长期治疗未报告新的安全性问题。
核心结论
- 长期每周皮下托珠单抗 162 mg 治疗难治性大动脉炎具有激素节约效应并改善患者健康状态,未发现新的安全性问题。
研究设计与样本
- TAKT 研究为随机双盲安慰剂对照试验,完成双盲期的 36 例患者全部进入开放标签延长期,接受每周皮下托珠单抗 162 mg 最长超过 96 周,其中 28 例接受治疗 96 周。
主要发现
- 糖皮质激素中位剂量在入组前复发时为 0.223 mg/kg/日,治疗 48 周后为 0.131 mg/kg/日(四分位距 0.099, 0.207),96 周后为 0.105 mg/kg/日(四分位距 0.039, 0.153)。
- 46.4% 患者将激素剂量减至 <0.1 mg/kg/日,低于入组前复发时剂量的一半(平均差 -0.120 mg/kg/日;95% CI -0.154, -0.087)。
- 96 周时影像学评估显示 17.9% 患者疾病改善、67.9% 稳定。
- 36 项短期健康调查(SF-36)的躯体与心理成分总结评分及 8 个领域中的 7 个领域评分较基线临床改善并在 96 周治疗期间维持。
临床怎么用
- 对难治性大动脉炎患者,可考虑每周皮下托珠单抗 162 mg 长期治疗以实现激素减量并维持疾病稳定。
局限性
- 开放标签延长期研究,糖皮质激素减量由研究者酌情决定,缺乏对照组。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the long-term efficacy and safety of the IL-6 receptor antibody tocilizumab in patients with Takayasu arteritis (TAK). METHODS: Patients completing the randomized, double-blind, placebo-controlled period of the TAKT (Takayasu arteritis Treated with Tocilizumab) trial were followed up during open-label extended treatment with weekly s.c. tocilizumab 162 mg for up to 96 weeks or longer, with oral glucocorticoid tapering performed at the investigators' discretion. Endpoints of the extension analysis included steroid-sparing effects of tocilizumab, imaging data, patient-reported outcomes (36-Item Short Form Health Survey) and safety. RESULTS: All 36 patients enrolled in the double-blind period entered the open-label extension; 28 patients received tocilizumab for 96 weeks. The median glucocorticoid dose was 0.223 mg/kg/day at the time of relapse before study entry, 0.131 mg/kg/day (interquartile range 0.099, 0.207) after 48 weeks and 0.105 mg/kg/day (interquartile range 0.039, 0.153) after 96 weeks. Overall, 46.4% of patients reduced their dose to <0.1 mg/kg/day, which was less than half the dose administered at relapse before study entry (mean difference -0.120 mg/kg/day; 95% CI -0.154, -0.087). Imaging evaluations indicated that most patients' disease was improved (17.9%) or stable (67.9%) after 96 weeks compared with baseline. Mean 36-Item Short Form Health Survey physical and mental component summary scores and 7 of 8 domain scores were clinically improved from baseline and maintained over 96 weeks of tocilizumab treatment. No unexpected safety issues were reported. CONCLUSION: These results in patients with Takayasu arteritis provide evidence of a steroid-sparing effect and improvements in well-being during long-term treatment with once-weekly tocilizumab 162 mg, with no new safety concerns. TRIAL REGISTRATION: JAPIC Clinical Trials Information, http://www.clinicaltrials.jp/user/cteSearch_e.jsp, JapicCTI-142616.
引用
- Nakaoka Y, Isobe M, Tanaka Y, et al. Long-term efficacy and safety of tocilizumab in refractory Takayasu arteritis: final results of the randomized controlled phase 3 TAKT study. Rheumatology (Oxford). 2020. PMID: 31951279. doi:10.1093/rheumatology/kez630
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。